Nebulized Colistin And Continuous Cyclic Azithromycin In Severe COPD Patients With Chronic Bronchial Infection Due To <i>Pseudomonas aeruginosa</i>: A Retrospective Cohort Study.

The mixed model applied showed that combination therapy with nebulized colistin and continuous cyclic azithromycin attained an estimated mean reduction in ECOPD of 38.3% with respect to baseline after 24 months ( Figure 2 ), and parallel reductions in hospitalizations and hospital stays of up to 41.5% and 41.9% respectively ( Figures 3 and 4 ).The data of the fixed effects of the model applied for ECOPD, hospitalizations and days of hospital stay are detailed in Tables 3 – 5 ; they reached statistical significance for ECOPD frequency, and borderline significance for hospitalizations due to respiratory disease.

also in 7,017 other papers